Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
FB

NASDAQ · FBIOP

Fortress Biotech, Inc.

Healthcare · Biotechnology

$17.84

Up+$0.06 (+0.34%)

Updated Oct 11, 2026, 6:59 AM

SID Score

6.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
60.62M
P/E ratio
11.44
Dividend yield
0.00%
52-week range
$12.50 – $21.43
Volume
822
Avg. volume
15.83K

Price performance · FBIOP

FBIOP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

FBIOP closed at $17.84 after 20 trading sessions, down 3.25% for the selected period.

Last close
$17.84
Period change
-3.25%
Period low
$16.06
Period high
$18.58
Daily close
View OHLC price history
FBIOP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$17.85$17.85$17.6201$17.84822
Oct 8, 2026$17.74$17.9563$17.40$17.78016.31K
Oct 7, 2026$17.5001$18.1588$17.5001$18.02924.06K
Oct 6, 2026$18.00$18.58$17.5001$18.584.89K
Oct 5, 2026$16.95$18.10$16.95$18.1030.17K
Oct 2, 2026$16.20$17.245$16.20$16.8625.19K
Oct 1, 2026$16.31$16.38$16.05$16.067.29K
Sep 30, 2026$16.37$16.70$16.37$16.5116.22K
Sep 29, 2026$16.64$16.94$16.0376$16.6758.83K
Sep 28, 2026$16.7599$16.7599$16.40$16.5210.39K
Sep 25, 2026$16.82$16.86$16.375$16.64564.91K
Sep 24, 2026$17.00$17.025$16.79$16.82513.3K
Sep 23, 2026$17.10$17.1396$16.855$17.0515.93K
Sep 22, 2026$18.00$18.00$17.10$17.157.33K
Sep 21, 2026$17.80$17.80$17.25$17.276.8K
Sep 18, 2026$18.00$18.00$17.62$17.792.79K
Sep 17, 2026$18.31$18.31$16.71$17.9019.13K
Sep 16, 2026$18.2002$18.30$18.10$18.1110.27K
Sep 15, 2026$18.35$18.35$18.19$18.197.32K
Sep 14, 2026$18.45$18.45$18.44$18.441.31K

Latest FBIOP news

The latest Smart Investors Daily articles mentioning FBIOP.

Stock researchCompany · Overview

FBIOP research

Overview

Company profile and research snapshot.

Company profile

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$28.51
Implied upside
—
Analysts
8
FBIOP recent ratings
DateFirmRatingTarget
Feb 23, 2026HC Wainwright & Co.Buy—
Aug 21, 2025HC Wainwright & Co.Buy—
Mar 11, 2025Roth MKMBuy—
Nov 18, 2024HC Wainwright & Co.Buy—
Jul 19, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Journey Medical Corporation to Participate in September 2026 Investor Conferences

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences. Details of

Yahoo · Sep 8, 2026

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The prese

Yahoo · Aug 13, 2026

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO® and UNLOXCYT™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biophar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By